Total trials
105
Active
56
Phase 3
4
Total enrollment
8,949
Pipeline matrix
Showing 40 of 56 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Chemotherapy | — | — | — | — | 6 | ||
| Carboplatin | — | — | — | 7 | |||
| Etoposide | — | — | — | 6 | |||
| Sintilimab | — | — | — | — | 5 | ||
| Tislelizumab | — | — | — | — | 4 | ||
| Cisplatin | — | — | — | 5 | |||
| Immunotherapy | — | — | — | — | 2 | ||
| Ivonescimab | — | — | — | — | — | 2 | |
| blinatumomab | — | — | — | — | 3 | ||
| Chidamide | — | — | — | — | 6 | ||
| Ruxolitinib | — | — | — | — | — | 2 | |
| fruquintinib + sintilimab + SOX | — | — | — | — | — | 1 | |
| Sinitilimab+SOX | — | — | — | — | — | 1 | |
| neoantigen-loaded dendritic cell vaccine | — | — | — | — | — | 1 | |
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| gemcitabine ,oxaliplatin,anlotinib,Sintilimab | — | — | — | — | — | 1 | |
| serplulimab | — | — | — | — | — | 1 | |
| High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy | — | — | — | — | — | 1 | |
| Sacituzumab Tirumotecan and Anlotinib | — | — | — | — | — | 1 | |
| Sugemalimab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Ensatinib | — | — | — | — | — | 1 | |
| AK104 | — | — | — | — | — | 1 | |
| AK112 | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| S-1 | — | — | — | — | — | 1 | |
| S-1, Oxaliplatin sintilimab HIPEC | — | — | — | — | — | 1 | |
| Sunvozertinib | — | — | — | — | — | 1 | |
| PD-1 Inhibitor plus Chemotherapy | — | — | — | — | — | 1 | |
| Low-Dose Radiation | — | — | — | — | — | 1 | |
| BL-B01D1 | — | — | — | — | — | 1 | |
| Almonertinib | — | — | — | — | — | 1 | |
| Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses. | — | — | — | — | — | 1 | |
| Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses. | — | — | — | — | — | 1 | |
| Cadonilimab | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Adebrelimab | — | — | — | — | — | 1 | |
| Toripalimab | — | — | — | — | 3 | ||
| SYS6010 | — | — | — | — | — | 1 | |
| Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy | — | — | — | — | — | 1 |
16 more active programs hidden
Next readouts
- 2023-12-31
- 2024-04-30
- 2024-07-31
- 2024-08-31
- 2024-09-30
- 2024-09-30
- 2025-03-28
- 2025-06-30
- 2025-07-31
- 2025-12-15
Top conditions
- Esophageal Cancer6
- Gastric Cancer5
- Esophageal Squamous Cell Carcinoma (ESCC)3
- Immune Checkpoint Inhibitors (ICIs)3
- Esophageal Squamous Cell Carcinoma3
- Leukemia, Lymphoid3
- Extensive-stage Small-cell Lung Cancer3
- NSCLC3
Frequently asked questions about Sichuan University
- How many clinical trials does Sichuan University have on ClinicalTrials.gov?
- Sichuan University is listed as the lead sponsor on 105 clinical trials in ClinicalTrials.gov, 56 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sichuan University's trials are in Phase 3?
- 4 of Sichuan University's trials are in Phase 3, spread across 56 active drug programs.
- What therapeutic areas does Sichuan University focus on?
- Sichuan University's most-studied conditions on ClinicalTrials.gov are Esophageal Cancer, Gastric Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitors (ICIs), Esophageal Squamous Cell Carcinoma.
- When are Sichuan University's next clinical trial readouts?
- Sichuan University has 10 upcoming primary-completion readouts tracked here; the soonest is “Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT”, expected around 2023-12-31.